BB Biotech AG (CHIX:BIONZ) Accounts Payable: CHF Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BIONZ BB Biotech AG CHIX:BIONZ
15 GF Score
Price CHF51.80
! 3 Warning Signs
View Full Analysis

What is BB Biotech AG Accounts Payable?

BB Biotech AG CHIX:BIONZ 15 Accounts Payable is CHF Mil as of Jun. 2026. GuruFocus rates CHIX:BIONZ with a GF Score™ of 15/100. The stock has 3 warning signs investors should review.

BB Biotech AG's Accounts Payable for the quarter that ended in Jun. 2026 was CHF Mil.

BB Biotech AG Accounts Payable Related Terms

BB Biotech AG Accounts Payable Historical Data

* Premium members only.

The historical data trend for BB Biotech AG's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG Accounts Payable Chart

BB Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BB Biotech AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
CHIX:BIONZ
15GF Score
BB Biotech AG CHIX:BIONZ
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BB Biotech AG Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF Mil mean?
BB Biotech AG (CHIX:BIONZ) has a Accounts Payable of CHF Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BB Biotech AG and its competitors.
Is BB Biotech AG's Accounts Payable too high?
BB Biotech AG's current Accounts Payable is CHF Mil. Overall, BB Biotech AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Accounts Payable compare to VRTX and REGN?
BB Biotech AG's Accounts Payable of CHF Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BB Biotech AG and its competitors. BB Biotech AG's current Accounts Payable is CHF Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (CHIX:BIONZ) has a current Accounts Payable of CHF Mil. The current Accounts Payable is CHF Mil. BB Biotech AG's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For BB Biotech AG (CHIX:BIONZ), the current Accounts Payable is CHF Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BB Biotech AG Business Description

Other Exchanges BION:Switzerland
Address Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a Swiss investment company listed on the SIX Swiss Exchange, with a focus on the biotechnology sector. It invests primarily in listed biotechnology companies that develop and market novel drugs with clear value to the healthcare system. The portfolio is concentrated in a relatively small number of holdings, mostly in the United States and Europe, including companies active in areas such as oncology, immunology, and rare diseases. BB Biotech is managed by Bellevue Asset Management, and its shares trade alongside a net asset value that is published regularly. The company generates returns mainly through capital appreciation of its equity holdings rather than through operating revenue, and it distributes dividends to shareholders. It provides investors with exposure to a diversified portfolio of biotechnology equities.
15GF Score

Get the complete analysis for CHIX:BIONZ

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF51.80
Price